Helix BioPharma reports Q2 2008 highlights, financi...( AURORA ON March 10 / Helix BioPha...)

AURORA, ON, March 10 /PRNewswire-FirstCall/ - Helix BioPharma Corp. (TSX, FSE: "HBP") today reported its highlights and financial results for the three and six months ended January 31, 2008.

HIGHLIGHTS

The Company's highlights for the quarter included:

- The signing of an agreement with KBI BioPharma for the development of

a clinical packaging format for L-DOS47, Helix's therapeutic

candidate for lung adenocarcinoma;

- The strengthening of the Company's cash position with the completion

of a CDN$16.9 million private placement of common shares on

December 19, 2007; and

- A shareholder vote in favor of management at the annual general

meeting on January 29, 2008.

"We have a solid base on which we can continue the advancement of our lead clinical compounds," said John Docherty, President of Helix BioPharma. "Recent developments include our receipt of positive Phase II data for our Topical Interferon Alpha-2b, the preparation of a format of L-DOS47 that is suitable for clinical testing, and the strengthening of our balance sheet. We are currently developing plans for Topical Interferon in an expanded patient population and we are anticipating L-DOS47 entering the clinic in a Phase I study."

RESULTS FROM OPERATIONS

Three and six months ended January 31, 2008, compared to same periods in

previous year

Total revenue was negatively impacted by lower sales of Orthovisc(R) in Canada for both the three and six month periods ended January 31, 2008. Overall expenditures were lower in the second quarter ended January 31, 2008 and is mainly attributable to higher costs in the same period a year ago, associated with the Company's annual shareholder meeting. On a year-to-date basis, overall expenditures were marginally lower, with the one-time charge in the first quarter of fiscal 2008 related to the resignation of the Company's Chairman bei
'/>"/>